Skip to main content
OpenTrials
Completed

NCT Number: NCT06983509

Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy

This is a multicenter, prospective, registry study. By collecting relevant demographic information and clinical data of patients receiving continuous renal replacement therapy (CRRT) with pre-mixed solutions, the clinical applicability of pre-mixed solutions will be evaluated in critically ill patients in real-world clinical settings.

This study will be carried out in approximately 10 study sites in China. Patient data will be collected to evaluate the clinical applicability of pre-mixed solutions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Insufficiency Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Urogenital Diseases Urologic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Loading trial locations.

About this study

Treatment observation period: From initiation of the first CRRT with sponsored pre-mixed solutions to cessation of the pre-mixed solutions. The duration of this period can be up to 10 days.

Follow-up period: from the cessation of sponsored pre-mixed solutions to Day 30 after starting treatment with the pre-mix solutions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 ≤ age < 80 years old.
  • Patients admitted to the intensive care unit (ICU) and in need of CRRT.
  • Patients are willing to receive CRRT with at least one of three pre-mixed solutions:

Regiocit, Biphozyl, or Prismasol 2.

Exclusion criteria

  • Patients with chronic kidney failure who are receiving maintenance dialysis.
  • Patients expected to require the premixed solution for less than 24 hours.
  • Patients who are allergic or have contraindications to components of pre-mixed solutions, as determined by the investigators.
  • Patients who have participated in other interventional studies within the last 30 days.
  • Patients who are pregnant, breastfeeding, or abortus imminence.

Treatment and study plan

Regiocit

Drug

Regiocit can be used as a replacement fluid for CRRT with RCA. It will be used in pre-dilution mode only.

At least 200 mL of post-replacement solution is recommended to minimize clotting in the de-aeration chamber. A replacement/dialysate solution with 22 to 26 mEq/L bicarbonate buffer is advised as the first choice. A higher concentration of bicarbonate may be required in severe cases of acidosis. The use of a non-calcium-containing dialysate or replacement fluid is advised. The rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Regiocit will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 to 4 mmol/L. A BFR between 100 to 180 mL/min will be advised; a lower BFR can minimize patient citrate exposure, particularly in patients with lower body weight.

Other names: Sodium citrate replacement solution

Biphozyl

Drug

Biphozyl is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter. After the initiation of RRT, Biphozyl is used for late treatment of the acute condition when pH, potassium, and phosphate concentrations return to normal. Biphozyl can also be used if any other buffer is in use or during RCA.

The volume and rate of administration of Biphozyl depend on the blood concentration of phosphate and other electrolytes, acid-base balance, body fluid balance, and overall clinical condition of the patient. The volume of replacement fluid given also depends on the expected intensity (dosage) of treatment.

Other names: Phosphorus/sodium bicarbonate replacement solution

Prismasol 2

Drug

Prismasol 2 is used as a replacement fluid during CRRT. It is injected into the extracorporeal circuit before (pre-dilution) or after (post-dilution) the filter.

The volume and rate of administration of Prismasol 2 depend on the blood concentration of electrolytes, acid-base balance, fluid balance, and overall clinical condition of the patient. The volume of replacement fluid administered also depends on the required intensity (dosage) of the treatment.

Other names: Sodium bicarbonate replacement solution

Primary outcomes

  1. Filter Lifespan - Duration

    Time frame: From initiation of 1st CRRT with sponsored solutions until mandatory replacement at 72 hours, death, access problems, filter or circuit clotting, filter membrane rupture, elective stopping of the filter, or achievement of treatment goals, whichever first

    The duration of filter use during the use of pre-mixed solutions

  2. Filter Lifespan - Replacement or Discontinuation

    Time frame: From initiation of 1st CRRT with sponsored solutions until mandatory replacement at 72 hours, death, access problems, filter or circuit clotting, filter membrane rupture, elective stopping of the filter, or achievement of treatment goals, whichever first

    The reasons for replacing or discontinuing the filter during the use of pre-mixed solutions

  3. Electrolyte and Acid-Base Indicators - Calcium

    Time frame: Within 4 hours before the start of CRRT (baseline), 2h ± 1h, 6h ± 2h after the start of CRRT, and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Serum ionized calcium, total calcium and post-filter ionized calcium

  4. Electrolyte and Acid-Base Indicators - Potassium

    Time frame: Within 4 hours before the start of CRRT (baseline), and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Potassium

  5. Electrolyte and Acid-Base Indicators - Sodium

    Time frame: Within 4 hours before the start of CRRT (baseline), and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Sodium

  6. Electrolyte and Acid-Base Indicators - Phosphate

    Time frame: Within 4 hours before the start of CRRT (baseline), and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Phosphate

  7. Electrolyte and Acid-Base Indicators - Magnesium

    Time frame: Within 4 hours before the start of CRRT (baseline), and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Magnesium

  8. Electrolyte and Acid-Base Indicators - Bicarbonate

    Time frame: Within 4 hours before the start of CRRT (baseline), and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Bicarbonate

  9. Electrolyte and Acid-Base Indicators - pH

    Time frame: Within 4 hours before the start of CRRT (baseline), and daily after 24h of CRRT initiation until the end of use of the pre-mixed solutions during the 1st CRRT session.

    Blood pH value

  10. User experience of the pre-mixed solutions

    Time frame: At the end of the study, i.e., Day 30 post treatment

    A questionnaire about the preparation time, ease of operation, and additional workload when using the pre-mixed solutions will be provided to the investigators to collect information on user experience.

  11. Severe bleeding events

    Time frame: From initiation of the 1st CRRT with sponsored solutions until Day 7 post treatment

    • The requirement to transfuse 400 mL of whole blood or more than 2U of red blood cell suspension/concentrated red blood cells due to bleeding in a single time.
    • Bleeding that requires reoperation
    • New-onset intracranial hemorrhage without traumatic events.

  12. Citrate accumulation

    Time frame: From initiation of the 1st CRRT with sponsored solutions until Day 7 post treatment

    Defined as a total/ionized calcium ratio in serum >2.5, with metabolic acidosis (as determined by the investigator)

Sponsors and collaborators

Lead sponsor

Vantive Health LLC

Industry

Registry information

Official study title

Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy (PrioR): a Multicenter, Prospective Real-world

Acronym: PrioR

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 21, 2025
Registry last updated
Apr 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.